Doors and Okay. All right. I am being told we are ready to go. Good morning. We are, I guess, officially day three of Jefferies London Healthcare Conference. Really appreciate everybody's interest and attention here in the room and also on the webcast if you are listening in. I am Dave Windley with Jefferies Healthcare Equity Research, cover the pharma services space for Jefferies and have for longer than I would like to admit. We are kicking off the day this morning with the West Pharma management team. I am really grateful for their attendance here. Michel Lagarde is the company's President and CEO, Bob McMahon, the company's CFO. Michel, as you may have seen, joined recently from having served for a decade or so as COO of Thermo Fisher, and Bob, CFO last year, having come over from Agilent.
Agilent, Hologic, and in that regard, I have stolen both of you from Tyco, I guess.
Grateful for that. Thank you both for being here. Michel, let me kick you off around a topic that we talked about now a couple of times, customer engagement. You have identified and described one of the findings in your early days at the company is a level of customer interaction at West that is kind of at the tactical level, and your desire, you think, opportunity to elevate that to higher levels in the organization. Maybe talk about, expand on that observation. What interactions have you been able to kind of elevate so far, and then the benefit to the organization of getting to that point eventually?
Yeah. No. Good morning, everybody. I think the way to think about it is, the logical call point for us is really the head of supply at these pharma and biotech companies. These are people that report to the CEO and design basically the physical supply chains of the drugs that they are developing. As you said, I think historically, West was more connected at sort of the procurement level and taking the orders and processing them. That is obviously critically important, but it is probably not the place you will find sort of the best insights around what are the next set of needs, understand a little bit more about the different scenarios of demand, and importantly, make progress towards getting our best products be chosen as the standards for these pharma companies.
I have obviously had the benefit in my last job to be the largest supplier to all of these people, and so connecting with them is not hard. I think what I found is that they are very interested in connecting with us at that level and have a conversation more around, hey, what problems can we help resolve? How do we make sure that as they design their manufacturing standards, that they understand our innovation roadmap and that they can look a little bit ahead of not just marketed products on our side, but also solutions that we are still developing to see how they would fit in with the needs that they have. I think the way it has been going is, we have had obviously our initial touchpoints for me to say hello to them again from the new spot.
The next set of logical follow-ups is visiting each other's sites. It turned out also that lots of these folks that are customers had never really seen our manufacturing operations, so they're quite keen in understanding what that looks like. Similarly, our teams, I think, love going through the place of manufacturing where our products are actually used, right? We're sort of in that active phase, and with that, I think we'll come out with a set of agendas that is sort of customer-specific around making sure that these connections happen, that we have a sort of set cadence and governance around engaging with them so that we can pick a couple of topics, whether that's innovation adoption or whether that is contamination control strategies or sort of elements of things that matter to them, matter to us, make progress against that.
I think over time, I've learned you do that with some regular cadence to it, this is how you build relationships.
Sure. That's very helpful. In terms of the steps, so it seems like you're describing tightening with them, showing them your innovation agenda within what I might think of as kind of the core elastomer franchise. Am I right in thinking that a next step to that is also evaluating and getting an understanding of what more can we do for that client and how does that drive your longer-term strategic plan? When does that feather into those discussions?
Yeah. I think what you get by spending time with these people is you get a much richer understanding of the complexities of the supply chains that they manage, because not only the sort of commercial products and the supply chains associated with that, but the complexity gets enhanced because they look down the R&D pipeline and they see all the projects that are coming, right? Some of them come through their own R&D efforts. A lot of those come through the biotechs that they acquire or products that they in-license, so they inherit a set of choices somebody else has made.
I think, which is a true statement, I think, for all of our large customers, they now have needs across different delivery technologies, needs across different modalities, and as a result, I think just better understanding what those things are will give us good input into making sure that we always have products that are relevant to the needs that they have, but also allows us to think about, "Hey, these are the challenges that they face, and perhaps there's an opportunity for us to add capabilities or products to our product set that would logically fit and would be logical extensions to what we offer.
Right.
I'd say we're in the very early innings of just taking inventory of that. Some of that is quite obvious. You don't need to be a rocket scientist to think through those. But I think just establishing those relationships and getting those conversations going is going to be the main source of insight around what else to add over time.
Yeah. That's perfect. Thank you for that. On this topic, I'm interested in how you see this evolving as a way to perhaps set expectations around the timing. I think inorganic opportunities start to become part of that potential picture as you get that greater and broader understanding of those client needs and their own path. But to set expectations appropriately about when you would have enough information, enough understanding from the portfolio of clients to then make wise decisions about which way to go in an inorganic strategy.
Yeah. I think it's hard to pin down a specific time. The way I think about it, when Bob and I wake up, we think about strengthening the organic profile of the company first, right? If you think about sort of the tailwinds that we have on demand, the opportunities to continue to drive a upgrade strategy that then obviously has a margin expansion component to it. We're at the very early innings of driving productivity at the sort of next level of impact. These are all the things that I think will create a lot of economic value and a lot of benefit to our customers. Those are the things we think about first, right? And the list on that is long and deep.
But yes, throughout the conversations too, these customers are quite explicit about their desires to simplify their supply chains, deal with less suppliers, consolidate their needs with a couple of trusted partners. I can't point you to a specific timeframe, but the beauty we have is we can be incredibly disciplined and patient, because as said, the organic prospects that we have are awesome, and we'll continue to capitalize on those. As we go about, we'll have the opportunity to evaluate whether it makes sense to do something inorganically.
Got it. I want to come back. Let's come back and focus on the core, the elastomer, high-value business, and I'm going to get a little more tactical here. One of the other suppliers into the GLP-1 originator franchise recently gave us some news that they saw a material reduction in order expectations for 2027. That's obviously an important franchise for West, and kind of conversely, was a really, really strong performer in the third quarter. What are you seeing in the latest customer trends, forecasts for the kind of typical forecast period coming to the end of this year and out into next year?
Yeah. I think for us, I can't comment on the specifics of others, but for us, I think we've always thought about this strategy of one of broad participation. I think I've been long enough in the drug development and manufacturing business that I've concluded that I'm certainly not smart enough to pick winners. I know you are, Dave. But our strategy is just make sure we're spec'd in on everything, and then we'll see how sort of the cards fall for the individual players. I think that is true on the GLP-1 space for us today. It's true by making sure that we're broadly spec'd into the commercial products that already are on market. We make sure that we have very high participation in the next wave of innovation that is currently through the clinic.
Then obviously, we will make sure that as these products go generic, that the biosimilar companies will logically just pick the components that the innovator has chosen so that they don't introduce more variability into their needs to be bioequivalent. That's sort of how we play it. When you look at it that way, we can therefore look at sort of the aggregate demand for the class, and I think all the signs on that are positive, right? There continues to be new clinical data that shows that more patients will benefit from these medicines. There continues to be more access for patients, both in the U.S. and Europe, as well as places around the world where these first generics are now showing up.
As a result, I think we can conclude on it that GLP-1s continue to be a robust, transformative medicine that we are seeing as a tailwind to our growth. Bob, maybe you want to add some specifics.
I think that's right. As we think about this, our elastomers business, GLP-1s represent about 10% of our total company's revenue. As you said, we're fortunate enough to be able to participate broadly in the market, and that's how I would think about this going forward. There's still a lot of opportunity in terms of market access as well as next-generation technologies and products that are going in. We're still optimistic about the long-term growth prospects of the GLP-1 class. I would say, what's beautiful about the West business is we are more than just GLP-1s as well. If you think about the HVP business, and I'm sure we'll talk about it, that has also been a strong growth driver for us, and particularly around some of the [upgrade] opportunities as well.
There's not just GLP-1s that are providing the growth for the company. It's really broad-based.
Really? There's other things besides GLP-1?
Yeah.
On this, apologies, but to stick on this for a second, can you describe, and maybe this applies to non-GLP-1 as well, but the cadence of order forecasts that your clients give you and the visibility, like, how does that roll?
Yeah, so I would say in the typical formats, you engage customers annually, sort of around this time of year, a little earlier, but get a sense of sort of what the year looks like. I think even though the demand doesn't follow a calendar, I think business planning cycles that these companies do. I think that's also one of the elements to your earlier question on why does it make sense to build some more of these strategic relationships. I think historically, the company only benefited from hearing from the procurement people, "These are the orders that we're going to place with West for the next years," without a lot of context around it, right? I think by hanging out with a couple more senior people, you get more of the, "Hey, what are actually the variables on the inputs?
What are the clinical cards that are getting turned over? Which are the countries that we're now going to launch in?" So you have a better sense of what's the possible different demand scenarios. But I would say typically people give us a good sense of what the next year looks like, and then the closer you get by, the more firm those order patterns become.
On this, attempting to pin you down a little bit, but on this, do you feel like at this point you could say rule out that when you are prepared, you don't have any knowledge today that you have a kind of an unusual and outsized headwind to your growth, and that we shouldn't be surprised when you do provide guidance on 2027?
Well, you will tell me in February when we do, whether you are satisfied. I think the way we think about it, we have such a diversified set of customers and products that we feel really good at the, even though you have movement at the sort of individual product level, in the aggregate, what we are excited about is that sort of all the things that drove our business over the last couple years, these are really lasting trends, and therefore you would expect them to be there in the period ahead.
Got it.
Yeah.
Let us move beyond GLP-1s to this supposed other part of the business. The Annex 1 and related HVP conversion, I think we are broadening the term these days because it is not EU Annex 1 regulation alone, but that upgrade cycle continues to blossom. Maybe talk about kind of total projects, the amount that is still in conversion, how much in production, and how you think about that as an algo driver—
Yeah
—into the future.
You want to provide some of that?
Yes, so maybe to provide just a quick kind of context for kind of dimensionalizing some of these, because we are very excited about this opportunity. It continues to be a good growth driver for us. We have talked about an incremental 200 basis points of growth this year for just this upgrade opportunity. We have got over 800 projects either that have been completed or are currently being worked on in a pipeline of even more projects. What started out as primarily or principally a European initiative, we are really starting to see expand beyond the European geography as an example, in particular in the U.S. What is really good is we are probably about 20% penetrated, a little over 1 billion components have been upgraded in Europe out of the 6 billion that we have kind of quantified, but very early innings in the U.S.
I think this is something that we think is a durable tailwind for us for many years to come, as we continue to move up the reduction in contamination kind of paradigm, or continuum with our customers.
Yes, I think just for the benefit of the doubt, or state the obvious, these are involved activities for our customers, right? This is why I think your point around the funnel builds and then it takes a time to convert, because if you have a commercial product and you sell these commercial products in 133 countries around the world, then the refiling of using new components is a very involved effort, right? This is why I think we think of the durability of this tailwind both by means of the European regulation, but also the requirements that the FDA now puts on folks, that this is going to be with us for quite some time. I think the other aspect for us is that the upgrade strategy is an important one for our financials, right?
Because at similar volumes, the opportunity to get a lot more sort of economic participation as people upgrade, and as we upgrade to higher standard products, the margin percentage on those is higher too. You get a bit of the sort of double impact on similar volumes, higher priced, and on those higher price, you make a higher percentage margin.
Yeah, the incremental margin math on this is particularly eye-popping.
Yeah.
If volume doesn't change, price goes up, margin goes up a lot.
Yes. Yeah.
I have, in recent conferences, I ran into some folks who are a veteran person, in fact, who's in Europe and experiencing Annex 1, and I've talked with him about this. The reaction relative to the U.S. was, a lot of the U.S. is already in isolator. A lot of the U.S. would have already made this conversion. I hear you saying something different. I guess the basic question is, are there differences in the preexisting conditions in the U.S. versus Europe that would cause this upgrade cycle to proceed differently?
Yeah. Look, I would say there's a lot of global manufacturers that, in their efforts to comply with the Annex 1 requirements, thought about their entire global supply chains, right? Because the insights that the regulators had here in Europe, in a way, are not different than the regulators elsewhere in the world, right? They are on the same mission to make sure that products are being produced of high quality and without contamination. I think you're right. That's why I think Annex 1 was probably always a little bit too narrow of a label. It was more around people's contamination control strategies. I do think adoption and the pace at which people put effort against it is supported when the regulators tell you to, right?
That's not that these companies wouldn't have gone there by themselves, but if you have an inspection and an inspector has these observations in your Form 483, it's harder to resist, I would say. So it's certainly not the case that nobody in U.S. manufacturing didn't convert as part of their projects, but I do think we see a real additional—
Got it.
—set of projects associated with it.
Okay.
Yeah.
Sorry, go ahead.
As part of our conviction, we just announced a kind of a next wave of capital investments to take on more finishing capacity—
Finishing, yeah.
—to be able to take on this additional volume, finishing volume, that is.
An additional question on this topic. Is there a common theme in, we talked over breakfast that it could be standard to Westar, it could be Westar to something higher than that. Is there a more common version, use case, I guess, for lack of a better phrase?
Yeah. Look, I think we try to have a broad set of product solutions so that people can pick something that really fits well with their needs. I think part of it is you got to go to a minimum standard to satisfy the regulators, but then very quickly you think about, in this specific product, maybe because of the molecules that you're trying to contain, having extra protection is required. Maybe the drug substance cost of that specific product is so high that getting yourself to the highest tier sort of containment protection is sort of the best solution. So I think we're trying to make sure that, and obviously we engage our customers in those dialogues around how do we match up what you're trying to solve for with sort of the best product solution. In that, obviously, we have some bias.
We think our NovaPure products stand out in sort of all of the characteristics that they represent. As a result, we think we're pretty effective in demonstrating those benefits, and over time, have more people go up sort of that upgrade cycle.
That is great. Let us move, Bob, to your point about CapEx and this finishing cycle. Is it possible to frame the finishing capacity? You mold products, some go to finishing, some just go straight to the bag. How much additional finishing are you adding, or relative to what molding capacity you have, is there a way to frame the relative size of this?
Yeah. What we have said is it is a multi-year kind of investment. We have not talked about kind of the incremental capacity associated with that. What I would say is if we think about our manufacturing process, we believe we have sufficient capacity from a molding perspective, given the investments that we have already made around the globe. That will be able to carry us through at least the end of the decade here. What we are looking at doing is, as the volumes continue to increase in the finishing elements of this, which are a higher ROI because of that incremental price that we were talking about, that incremental value that we are capturing and the additional product value that the customers are seeing, is providing additional capacity there that will come online in the 2028, 2029 timeframe, or 2028 timeframe, late in 2028, as that volume continues.
We have sufficient capacity to continue to satisfy the demand now, but our expectation is that demand will continue to grow as the requirements for upgrading will continue to drive. Primarily here in the U.S.—
Okay
—as we think about those projects that are being developed right now.
Okay. From an aggregate CapEx standpoint, 2026 came down a little bit.
Yep
From the upper $200 million to the lower $200 million. I think you talked about still a 6%-8% range.
Correct.
Was the cut here at the end of 2026 some deferral? Was it greater efficiency on some projects or kind of deprioritization of some projects that you don't think you need to do anymore?
Yeah. It's a little of all of those. I think one of the things that, when I got here, I think I recognized is that the way we were allocating capital, CapEx investment, was probably not perfectly aligned with our strategic intent of driving the greatest growth. We obviously came off a high, elevated levels of capital spend, and I think this year what we have done is kind of reprioritized some areas, making sure also that the planning that we were doing, particularly for this investment, was putting the investments, the equipment in the places that made the most sense. That took a little more time than I would say we would have had in the past. I think that actually provides us with flexibility going forward.
We feel good about that 6%-8%, and we would expect to stay within that framework for the time being.
Okay. Moving on to margin. I believe the long-range plan framework, still 7%-9% growth, 100 basis points of margin expansion. In this particular year, you are on track to kind of 300 basis points of operating margin. Maybe talk about the unusually strong and drivers of unusually strong performance in 2026, and comment on what we might perceive as some of those things being enduring.
Yeah, just real quickly, we certainly have benefited from a number of things. Obviously, the HVP upgrades that we were just talking about. Volume has been greater than what we anticipated, and when you have more volume going through a fixed factory, it drives very good efficiency and margin expansion. We also had benefit of higher-than-expected price at the beginning of the year. As we think about going forward, we are kind of ahead of schedule, and I think we feel very good about that continued margin expansion. I wouldn't put 300 basis points per year in your models, but certainly, I do think that margin expansion, that 100 basis points, probably more next year because of the portfolio changes with SmartDose divestiture and so forth.
But I think margin expansion is an underappreciated element of our story, particularly as Michel talked about at the very beginning about this continuous improvement that we are still at the early days of that going forward.
I think I probably asked this question before, but in terms of thinking about that long-range plan, Michel, new to the company, coming in, evaluating a lot of things, is that also one of them?
Sure. No, look, I think proper business planning is that, right? You continue to think about understanding customer needs, understanding really well what drives the business. In our case, as we talked about, there's a couple of these really nice secular independent tailwinds that will drive demand, and I think there's always an opportunity to understand those better, make sure that we have a set of product solutions that meet those needs. And when you do that really well, you can translate that into an ambitious financial plan. I think that's always been part of the company's cadence and certainly something we will continue to work on, strengthen, and provide you with the output.
Got it. We'll listen for that updated long-range plan and the 275 basis points of margin expansion on the fourth quarter call.
And with that, thank you very much.
Thank you.
For those reading the transcript, I am kidding.
Yeah.
Yes, please.
Yeah. So, thank you very much, everybody, for listening in.
Thank you.